Right To Breathe, Right To Choose?

October 18, 2018 Danielle Twigg

There are currently 99 inhalation devices in the UK market for respiratory diseases. These products are either monotherapy or fixed-dose combinations of beta-agonists, anti-muscarinics, mast-cell stabilizers and inhaled corticosteroids (ICS). This research evaluates the potential challenges in choosing the right device by physicians and patients.

Authors: George Wang, Richard Macaulay

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
Pricing And Reimbursement Reforms In Spain – A Systematic Analysis Of National Pricing Decisions By The CIPM
Pricing And Reimbursement Reforms In Spain – A Systematic Analysis Of National Pricing Decisions By The CIPM

Next Article
Medicinrådet And The New Hospital Drug Appraisal Process In Denmark – The Story So Far
Medicinrådet And The New Hospital Drug Appraisal Process In Denmark – The Story So Far